Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nls Pharmaceutics Ltd (NQ: NLSP )

3.500 +0.130 (+3.86%)
Streaming Delayed Price Updated: 11:37 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nls Pharmaceutics Ltd

< Previous 1 2 3 4 5 6 7 Next >
NLS Pharmaceutics Announces Preclinical Data Demonstrating the Potential of NLS-4 (Lauflumide) to Treat Chronic Fatigue Associated With Long-COVID
STANS, SWITZERLAND / ACCESSWIRE / October 14, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and... 
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property Product Recall Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
36 of the Best Ideas Companies to Present at the Fall Harvest - Best Ideas from the Buy-Side Virtual Investor Conference on October 5th - 8th, 2021
RALEIGH, NC / ACCESSWIRE / October 4, 2021 / The Fall Harvest - Best Ideas from the Buy-Side will take place on October 5th - 8th, 2021, where 36 SmallCap, MicroCap and NanoCap public companies will be... 
From MicroCap Rodeo
Via AccessWire
NLS Pharmaceutics to Participate in The Micro Cap Rodeo Fall Harvest Conference: Best Ideas from the Buy-side
STANS, SWITZERLAND / ACCESSWIRE / September 30, 2021 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and... 
From NLS Pharmaceutics AG
Via AccessWire
NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment
STANS, SWITZERLAND / ACCESSWIRE / September 28, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery... 
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Regulatory
NLS Pharmaceutics to Participate in the Benzinga Healthcare Small Cap Conference
STANS, SWITZERLAND / ACCESSWIRE / September 24, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the... 
From NLS Pharmaceutics AG
Via AccessWire
NLS Initiates Phase 2 Trial for Quilience in Narcolepsy and Announces First Patient Enrolled
STANS, SWITZERLAND / ACCESSWIRE / September 14, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the... 
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Regulatory
NLS Pharmaceutics to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference
STANS, SWITZERLAND / ACCESSWIRE / September 8, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery... 
From NLS Pharmaceutics AG
Via AccessWire
38 Stocks Moving In Friday's Mid-Day Session
Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares climbed 45.8% to $6.27 after the company presented data from ongoing studies of its preventive vaccine against COVID-19, showing... 
Via Benzinga
Exposures COVID-19
58 Biggest Movers From Friday
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares climbed 204.1% to close at $19.16 on Friday. Regencell Bioscience reported partial exercise of underwriter... 
Via Benzinga
22 Stocks Moving in Friday's Pre-Market Session
Gainers GeoVax Labs, Inc.. (NASDAQ: GOVX) shares rose 72.1% to $7.40 in pre-market trading after the company announced it presented COVID-19 vaccine data at the European Society... 
Via Benzinga
Exposures COVID-19
NLS Pharma Stock Gains After Issuance Of Mazindol Patent
NLS Pharmaceutics Ltd (NASDAQ: NLSP) has received a Notice of Allowance from the U.S. Patent and Trademark Office for patent application No. 16/083,131. ... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Application Covering its Proprietary Mazindol Formulation
STANS, SWITZERLAND / ACCESSWIRE / August 19, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery... 
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Product Safety
NLS Pharmaceutics to Participate in the Canaccord Genuity 41st Annual Growth Conference
STANS, SWITZERLAND / ACCESSWIRE / August 5, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and... 
From NLS Pharmaceutics AG
Via AccessWire
NLS Pharmaceutics Announces the Appointment of Eric Konofal, M.D., Ph.D. as Chief Scientific Officer
STANS, SWITZERLAND / ACCESSWIRE / July 19, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of... 
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
NLS Pharma Stock Gains As Its Narcolepsy Candidate To Enter Mid-Stage Study Next Month
The FDA has accepted NLS Pharmaceutics Ltd's (NASDAQ: NLSP) Investigational New Drug application for Quilience (mazindol extended-release (mazindol ER), the... 
Via Benzinga
Exposures Product Safety
NLS Pharmaceutics Announces FDA Acceptance of IND Application to Initiate Clinical Trials with Quilience(R) (mazindol ER) to Treat Narcolepsy
Planned Phase 2a clinical trial anticipated to commence in August 2021 STANS, SWITZERLAND / ACCESSWIRE / July 15, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a... 
From NLS Pharmaceutics AG
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Product Safety
NLS Pharmaceutics to Present at the Access to Giving Virtual Investor Conference on July 15th
STANS, SWITZERLAND / ACCESSWIRE / July 9, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and... 
From NLS Pharmaceutics AG
Via AccessWire
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th - 15th, 2021. More than 50 companies are... 
From Access to Giving
Via AccessWire
35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021
RALEIGH, NC / ACCESSWIRE / May 27, 2021 / The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be... 
From MicroCap Rodeo
Via AccessWire
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
RALEIGH, NC / ACCESSWIRE / June 23, 2021 / Access to Giving - an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting... 
From Access to Giving
Via AccessWire
New Study Data Confirms NLS Pharmaceutics' Mazindol Orexin Pathway Activation For Sleeping Disorder
NLS Pharmaceutics Ltd (NASDAQ: NLSP) has announced new study data which support the mechanism of action for mazindol, the active compound in the Company's lead... 
Via Benzinga
30 Stocks Moving In Wednesday's Mid-Day Session
Gainers Discovery, Inc. (NASDAQ: DISCB) shares climbed 37.3% to $102.99. Grupo Televisa, S.A.B. (NYSE: TV) shares climbed 22.4% to $12.39 after the company reached an agreement... 
Via Benzinga
22 Stocks Moving in Wednesday's Pre-Market Session
Gainers Galectin Therapeutics Inc. (NASDAQ: GALT) rose 37.6% to $2.98 in pre-market trading after the company said a paper published in the peer-reviewed Journal for... 
Via Benzinga
50 Biggest Movers From Yesterday
Gainers Mackinac Financial Corporation (NASDAQ: MFNC) shares surged 60.7% to close at $21.16 on Tuesday after the company, and Nicolet Bankshares, jointly announced the execution... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.